Skip to content

NotablePeer-reviewed

CAR-T Cells Made Inside the Body

A targeted nanoparticle reprograms T cells into cancer fighters, skipping the factory.

ByTheresa Hunter, Yanjie Bao, Yan Zhang, Daiki Matsuda, Romina M. Riener, Annabel Wang and 2 others

National Institutes of Health · National Institute of Arthritis and Musculoskeletal and Skin Diseases · University of Pennsylvania · Parker Institute for Cancer Immunotherapy

What it is

The team packaged anti-CD19 CAR mRNA into lipid nanoparticles targeted to CD8+ T cells, reprogramming the cells directly inside the body rather than extracting and engineering them ex vivo. A single in vivo dose controlled tumors in humanized mice and drove durable B-cell depletion in nonhuman primates. The B cells that returned afterward were predominantly naive, a signature consistent with an immune system reset.

Why it matters

Conventional CAR-T therapy needs weeks of bespoke manufacturing plus lymphodepleting chemotherapy, confining it to a handful of specialized centers. Generating CAR-T in vivo could turn cell therapy into an off-the-shelf injection usable far more widely and for autoimmune disease as well as cancer. The paper has already drawn 258 citations and sits at a field-weighted citation impact of roughly 123, reflecting how quickly the approach has been taken up.

Underlined numbers link to their source. Every metric and quoted figure is listed under Sources and data below.

Filed underCAR-T, in vivo cell therapy, lipid nanoparticles, immunotherapy, mRNA

Scored 2026-09-30How scoring works

The Frontier Score, in full

How this entry's score is built, term by term. Open any pillar to see each sub-metric's raw value, how it maps to 0 to 100, and the record that holds it.
Evidence 85Impact 88Novelty 48
The three pillars as one shape: a result strong on every axis fills the triangle.
How the Frontier Score is calculated for this breakthrough
TermScoreWeightPoints
EvidenceHow established and verifiable the result is.85× 0.2521.1
ImpactHow much the result matters, judged field-relative and by current momentum.88× 0.2522.0
NoveltyHow genuinely new the result is, and how fast-moving.48× 0.5024.1
Weighted pillars67.2
Frontier recency15 months since publication× 0.63
IntegrityNot retracted× 1
Frontier Score42
Confidence: Settled. Established evidence: about 303 citations across 5 independent indices.Established evidence: about 303 citations across 5 independent indices.

Every sub-metric, traced to its source

Evidence85
Evidence sub-metrics
Sub-metricRaw value0 to 100WeightPointsSource
Peer review & venueWhether the work has cleared peer review, and how selective its venue is. Peer review is necessary but not sufficient: before citations accrue, a fresh result in the most selective venues (Nature, Science, Cell, NEJM, the Lancet, PNAS, Physical Review Letters/X) is a stronger evidence signal than one in a legitimate but very high-volume mega-journal, which in turn outranks a preprint that has not been reviewed at all.Maps to 0 to 100: Peer-reviewed article graded by venue prestige: flagship 100, elite-family 90, high-volume mega-journal 78. Review 90, book 70, dataset 60, preprint 45, other 55.Peer-reviewed1000.3030.0OpenAlex type / primary_location / source
CorroborationIndependent corroboration that the result is real and being taken up, read as the BREADTH of agreement rather than the size of the citation pile. Counts how many of the five independent citation indices (OpenAlex, Crossref, Semantic Scholar, OpenCitations, Europe PMC) report the work at all, plus orthogonal, non-citation lines of corroboration: entry into the encyclopedia, registered clinical trials, released datasets or software, public funding on record, and technical-community discussion. Citation MAGNITUDE is deliberately judged under Impact, not here, so Evidence and Impact measure genuinely different things instead of both rewarding the same citation pile twice.Maps to 0 to 100: Starts at 28 and rises with each of the five independent citation indices that agree the work is cited (+9 each) and each orthogonal non-citation corroboration line (+6 each: Wikipedia, clinical trials, open datasets or software, public funding, community discussion). Capped at 100.5 of 5 citation indices agree, 2 independent non-citation lines850.3025.5OpenAlex, Crossref, Semantic Scholar, OpenCitations, Europe PMC, DataCite, NIH RePORTER, Wikipedia, Hacker News count of agreeing indices + orthogonal reach
VerifiabilityHow openly the result can be read, reused, and reproduced. Rewards open access, a permissive reuse license (CC-BY/CC0), a green repository copy anyone can archive, openly minable full text, and released datasets or software a reader can actually run. Cross-checked across OpenAlex, Unpaywall, Europe PMC, and DataCite.Maps to 0 to 100: Closed 45; open access 80+; a permissive CC license 100; a repository copy, open full text, or a released dataset/software artifact each raise the floor.Closed access450.209.0OpenAlex, Unpaywall, Europe PMC, DataCite is_oa / license / has_repository_copy / open datasets
IntegrityRetraction and post-publication correction status. A retracted result is not evidence of anything and collapses the whole Frontier Score; a correction or expression of concern is a softer flag. Read across OpenAlex and Crossref (both update-to and updated-by notices).Maps to 0 to 100: Clean 100; a correction or expression of concern 75; retracted 0. Flagged if OpenAlex OR Crossref records the notice.No retraction or concern on record1000.2020.0OpenAlex, Crossref is_retracted / update-to / updated-by
Impact88
Impact sub-metrics
Sub-metricRaw value0 to 100WeightPointsSource
Field-normalized impactImpact relative to the world average for the same field, year, and type, so a small field and a large field are judged fairly. Triangulates three independent field-normalized measures: OpenAlex's Field-Weighted Citation Impact, its citation percentile within the exact field-and-year cohort, and the NIH iCite Relative Citation Ratio. 1.0x is average; the percentile is the share of same-field, same-year work it out-cites.Maps to 0 to 100: Each ratio (1.0 = field average) maps 1.0 to 50, 3.0 to 75, 9.0 to 90; the field+year percentile maps directly (top 1% -> ~99). The available measures are averaged. Falls back to a saturating citation count when none is available yet.131.8x FWCI, 57.3x RCR, top 0.0% of field-year vs field990.4544.6OpenAlex, NIH iCite fwci / citation_normalized_percentile / relative_citation_ratio
Influential citationsCitations that genuinely build on the work rather than mention it in passing (Semantic Scholar's influential-citation measure). A sharper signal of real impact than a raw count.Maps to 0 to 100: Saturating: 15 influential citations maps to 50. Falls back to a fraction of consensus citations when unavailable.17 influential530.2010.6Semantic Scholar influentialCitationCount
Citation velocityCitations received in the trailing twelve months, judged as a rate rather than a lifetime total. Momentum is what a frontier index cares about: a result being taken up fast right now is landing, whether its lifetime pile is large or still small. Where an expected field citation rate is known, the momentum is also read relative to it, so a fast-moving result in a quiet field is not overlooked.Maps to 0 to 100: Saturating: 30 citations in the last twelve months maps to 50. When NIH iCite provides the field's expected rate, this is blended evenly with the ratio of observed to expected momentum.272 in last 12 months (25.3x field rate)930.3532.6OpenAlex, NIH iCite counts_by_year / field_citation_rate
Novelty48
Novelty sub-metrics
Sub-metricRaw value0 to 100WeightPointsSource
Conceptual noveltyHow genuinely new the contribution is, measured at publication from the work's OWN content, not its date: how atypical its combination of research areas is versus all prior work, and whether it builds on a broad, deep base rather than only the newest papers in a fast-moving area. This is what separates a real advance from a recent-but-commodity result, and it needs no forward citations, so it is stable for brand-new work. An honestly noisy proxy (even state-of-the-art novelty measures agree only moderately with expert judgment), so it carries bounded weight and never drives the ranking alone.Maps to 0 to 100: Blends two publication-time signals, each 0-100: an atypical-combination score (how unusual the pairing of the work's research topics is versus the prior literature, by pointwise mutual information) and a foundational-reach score (median age and depth of the work's references). The stronger signal weighs 0.62, the weaker 0.38. When neither is measurable (a work too thin in topics or references), the pillar renormalizes over its recency signals instead.Nanowire Synthesis and Applications x Immune Cell Function and Interaction (178 prior works made this pairing); builds on refs a median 3.0y deep360.4516.2OpenAlex topics + referenced_works (publication-time)
RecencyHow recently the work appeared. The frontier is now, so newer scores higher.Maps to 0 to 100: Exponential decay with a 12-month half-life from the publication date.15 months old410.3012.3OpenAlex publication_date
Attention accelerationWhether attention is rising: citations in the latest full year versus the year before. Accelerating interest signals an active, opening frontier.Maps to 0 to 100: Latest/prior-year ratio: 1x maps to 50, 2x to 75, 4x to 100. Unknown is neutral.24.7x rising1000.1010.0OpenAlex counts_by_year
Edge of reviewPreprints and brand-new work sit ahead of the peer-review process. That earns novelty here (while it is discounted under Evidence), because it is where the frontier forms first.Maps to 0 to 100: Preprint 95, article <6 months 80, article <18 months 65, else 45.Peer-reviewed record650.159.8OpenAlex type / publication_date
ProvenanceAll sources

Sources and data

Every number behind this entry, grouped by the source that holds it: up to five citation indices cross-checked, field-normalized impact, then real-world reach (Wikipedia, community discussion, clinical trials, released data and public funding) where it exists. Each value links to its record.

OpenAlex

Primary record
Total citations
327
Field-weighted citation impact
131.8x field average
Citation percentile
Top 0.1% of its field-year
Citations, recent 12 months
272
Publication date
2025-06-19

Crossref

Citations
344
Works it builds on
41

Semantic Scholar

Citations, all versions
303
Influential citations
17

OpenCitations

Citations
127

Europe PMC

Citations
215

NIH iCite

Relative Citation Ratio
57.29x field average
Potential to translate
50%
Cited by clinical articles
1

NIH RePORTER

NIH grants funding it
1
NIH award funding
$19,735,689

Figures quoted in the write-up

FigureValueSource
Citations (OpenAlex cited-by count, high for a 2025 paper)258Science
Field-weighted citation impact (FWCI of 122.98, roughly 123x the average paper in its field)123Science
Biomedicine & HealthThe whole field

Back to the Frontier Index, or browse every breakthrough by date.

The Frontier Brief

The week's frontier, scored.

Every Monday, the highest-scoring new breakthroughs in the index, each with its score and a one-line read on why it matters. What you get

One email a week. The top new breakthroughs, scored. Unsubscribe anytime.